The company said that the trial "achieved its primary endpoint of non-inferiority for the composite cardiovascular (CV) endpoint." Merck announced only one additional detail: "Among secondary endpoints," they reported, "there was no increase in hospitalization for heart failure in the sitagliptin group versus placebo." The FDA has been wrestling for a number of years now with the problem of the cardiovascular effects-- whether positive or negative-- of diabetes drugs
We discuss how these drugs work to promote weight loss, the source of their side effects, and the newer compounds soon to overcome some of those side effects, such as muscle loss
Quick Tips It can be taken with warm milk as well
With consistent support and a personalized approach, this therapy empowers you to feel more in control of your body, your health, and your lifestyle every day
What the public usually sees, however, is marketing language
This timing synchronizes peak medication levels with active digestion when your stomach is most active